{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    12,
    13,
    14,
    15,
    16,
    18,
    22,
    24,
    26
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 1.0,
  "documentStructure": {
    "documentContentReferences": [
      {
        "id": "ref_1",
        "name": "Safety Update Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "1.6",
        "sectionTitle": "Lymphocytosis and Leukostasis",
        "description": "Safety information updated to align with the current IB"
      },
      {
        "id": "ref_2",
        "name": "Safety Update Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "1.7",
        "sectionTitle": "Clinical Safety of Ibrutinib",
        "description": "Safety information updated to align with the current IB"
      },
      {
        "id": "ref_3",
        "name": "Vital Signs Clarification",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "9.5",
        "sectionTitle": "Safety Evaluations",
        "description": "Additional pulse/heart rate and blood pressure assessments added"
      },
      {
        "id": "ref_4",
        "name": "Clinical Cutoff Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "9.1.5",
        "sectionTitle": "Clinical Cutoffs",
        "description": "Added reports of new malignancies to data collection after final PFS analysis"
      },
      {
        "id": "ref_5",
        "name": "Concomitant Medications Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.3",
        "sectionTitle": "Precautions with Concomitant Medications",
        "description": "Updated external links for classification of CYP3A inhibitors and inducers"
      },
      {
        "id": "ref_6",
        "name": "CYP3A Attachment Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Attachment 4",
        "sectionTitle": "Inhibitors and Inducers of CYP3A",
        "description": "Updated external links for classification"
      },
      {
        "id": "ref_7",
        "name": "Dose Modification Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "6.4.3.1",
        "sectionTitle": "Dose Modification for Subjects With Chronic Hepatic Impairment",
        "description": "Added instructions for dose modification based on Child-Pugh class"
      },
      {
        "id": "ref_8",
        "name": "Hemorrhage Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "12.3.3.1",
        "sectionTitle": "Major Hemorrhage",
        "description": "Reference to major hemorrhage reporting and definitions"
      }
    ],
    "commentAnnotations": [
      {
        "id": "annot_1",
        "text": "Janssen Research & Development is a global organization that operates through different legal entities in various countries.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Title Page",
        "pageNumber": 1
      },
      {
        "id": "annot_2",
        "text": "Vital sign assessments should be recorded in source documents but will not be routinely collected in the eCRF.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Table 1, Time and Events Schedule",
        "pageNumber": 6
      },
      {
        "id": "annot_3",
        "text": "Maximal tumor reduction defined as time of CR or when 2 consecutive CT scans show no further tumor reduction.",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Synopsis; Table 1; 9.2.1.2",
        "pageNumber": 13
      },
      {
        "id": "annot_4",
        "text": "For subjects with an increased risk of tumor lysis syndrome (TLS) or other toxicities, rituximab can be split over a 2-day period.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Table 2; 6.4.2",
        "pageNumber": 15
      },
      {
        "id": "annot_5",
        "text": "If a dose of study drug is not taken at the scheduled time, it can be taken as soon as possible on the same day.",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "6.3 Ibrutinib or Placebo Administration",
        "pageNumber": 14
      }
    ],
    "studyDefinitionDocumentVersions": [
      {
        "id": "ver_1",
        "versionNumber": "8.0",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2019-12-19",
        "description": "Update safety information regarding cerebrovascular accidents and clarify vital sign monitoring.",
        "amendmentNumber": "Amendment INT-7"
      },
      {
        "id": "ver_2",
        "versionNumber": "7.0",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2019-08-16",
        "description": "Halt collection of CR MRD samples except for new CR assessments.",
        "amendmentNumber": "Amendment INT-6"
      },
      {
        "id": "ver_3",
        "versionNumber": "6.0",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2017-07-12",
        "description": "Clarify DMC recommendations and update hepatic impairment dose modifications.",
        "amendmentNumber": "Amendment INT-5"
      },
      {
        "id": "ver_4",
        "versionNumber": "5.0",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2016-04-29",
        "description": "Addition of a second interim analysis at 180 PFS events.",
        "amendmentNumber": "Amendment INT-4"
      },
      {
        "id": "ver_5",
        "versionNumber": "1.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2012-12-20",
        "description": "Initial release of the clinical protocol.",
        "amendmentNumber": "Original Protocol"
      }
    ],
    "summary": {
      "referenceCount": 8,
      "annotationCount": 5,
      "versionCount": 5
    }
  }
}